JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

Inicio・Lista de Acciones・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Cerrado

SectorSalud

20.34 -1.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

20.19

Máximo

20.49

Métricas clave
By Trading Economics
Ingresos	11M -61M
Ventas	7.9M 46M
Margen de beneficio	-132.36
Empleados	270
EBITDA	6.3M -58M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+92.57% upside

Dividendos
By Dow Jones
Próximas Ganancias	2 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	731M 1.9B
Apertura anterior	21.75
Cierre anterior	20.34

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

9.91 / 14.15 Soporte y Resistencia

Syndax Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 feb 2026, 23:59 UTC

Charlas de Mercado

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

1 feb 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

1 feb 2026, 23:44 UTC

Charlas de Mercado

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

1 feb 2026, 12:47 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

1 feb 2026, 03:02 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

1 feb 2026, 03:01 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium Currently Owns Near 20% Stake in STT GDC

1 feb 2026, 03:01 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

31 ene 2026, 18:48 UTC

Adquisiciones, fusiones, absorciones

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31 ene 2026, 16:40 UTC

Ganancias

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31 ene 2026, 09:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30 ene 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30 ene 2026, 23:41 UTC

Charlas de Mercado

Deckers Outdoor Seen as Undervalued -- Market Talk

30 ene 2026, 23:12 UTC

Adquisiciones, fusiones, absorciones

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30 ene 2026, 22:20 UTC

Ganancias

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30 ene 2026, 22:10 UTC

Charlas de Mercado

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30 ene 2026, 21:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

30 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

30 ene 2026, 21:42 UTC

Ganancias

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 ene 2026, 21:36 UTC

Ganancias

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30 ene 2026, 21:33 UTC

Ganancias

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30 ene 2026, 20:42 UTC

Ganancias

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30 ene 2026, 20:37 UTC

Adquisiciones, fusiones, absorciones

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Comparación entre iguales

Cambio de precio

Syndax Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

92.57% repunte

Estimación a 12 meses

Media 39.11 USD 92.57%

Máximo 56 USD

Mínimo 27 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.91 / 14.15Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.